MYC-rearranged mature B-cell lymphomas in children and young adults are molecularly Burkitt Lymphoma

IF 12.9 1区 医学 Q1 HEMATOLOGY Blood Cancer Journal Pub Date : 2024-10-07 DOI:10.1038/s41408-024-01153-0
Sara Mato, Natalia Castrejón-de-Anta, Ariadna Colmenero, Lorenzo Carità, Julia Salmerón-Villalobos, Joan Enric Ramis-Zaldivar, Ferran Nadeu, Noelia Garcia, Luojun Wang, Jaime Verdú-Amorós, Mara Andrés, Nuria Conde, Verónica Celis, Maria José Ortega, Ana Galera, Itziar Astigarraga, Vanesa Perez-Alonso, Eduardo Quiroga, Aixiang Jiang, David W. Scott, Elias Campo, Olga Balagué, Itziar Salaverria
{"title":"MYC-rearranged mature B-cell lymphomas in children and young adults are molecularly Burkitt Lymphoma","authors":"Sara Mato, Natalia Castrejón-de-Anta, Ariadna Colmenero, Lorenzo Carità, Julia Salmerón-Villalobos, Joan Enric Ramis-Zaldivar, Ferran Nadeu, Noelia Garcia, Luojun Wang, Jaime Verdú-Amorós, Mara Andrés, Nuria Conde, Verónica Celis, Maria José Ortega, Ana Galera, Itziar Astigarraga, Vanesa Perez-Alonso, Eduardo Quiroga, Aixiang Jiang, David W. Scott, Elias Campo, Olga Balagué, Itziar Salaverria","doi":"10.1038/s41408-024-01153-0","DOIUrl":null,"url":null,"abstract":"<p>Aggressive B-cell non-Hodgkin lymphomas (NHL) in children, adolescents, and young adults (CAYA) include Burkitt lymphoma (BL), diffuse large B-cell lymphoma (DLBCL), and a subset of high-grade tumors with features intermediate between these entities whose genetic and molecular profiles have not been completely elucidated. In this study, we have characterized 37 aggressive B-NHL in CAYA, 33 with high-grade morphology, and 4 DLBCL with <i>MYC</i> rearrangement (<i>MYC</i>-R), using targeted next-generation sequencing and the aggressive lymphoma gene expression germinal center B-cell-like (GCB), activated B-cell-like (ABC), and dark zone signatures (DZsig). Twenty-two tumors had <i>MYC</i>-R without <i>BCL2</i> breaks, and two <i>MYC</i>-non-R cases had <i>BCL6</i> translocations. <i>MYC</i>-R cases, including DLBCL, carried BL-related mutations and copy number alterations. Conversely, <i>MYC</i>-non-R lymphomas had alterations in the B-cell receptor signaling/NF-κB pathway (71%). DZsig was expressed in 12/13 of <i>MYC</i>-R tumors but only in 2/10 of <i>MYC</i>-non-R GCB tumors (<i>P</i> &lt; 0.001). The 3-year event-free survival (EFS) of the whole cohort was 79.6%. <i>TP53</i> and <i>KMT2C</i> mutations conferred inferior outcome (3-year EFS <i>P</i> &lt; 0.05). Overall, <i>MYC</i>-R lymphomas in CAYA have a molecular profile similar to BL regardless of their high-grade or DLBCL morphology, whereas <i>MYC</i>-non-R has more heterogeneous genetic alterations closer to that of DLBCL.</p>","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"1 1","pages":""},"PeriodicalIF":12.9000,"publicationDate":"2024-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Blood Cancer Journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41408-024-01153-0","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Aggressive B-cell non-Hodgkin lymphomas (NHL) in children, adolescents, and young adults (CAYA) include Burkitt lymphoma (BL), diffuse large B-cell lymphoma (DLBCL), and a subset of high-grade tumors with features intermediate between these entities whose genetic and molecular profiles have not been completely elucidated. In this study, we have characterized 37 aggressive B-NHL in CAYA, 33 with high-grade morphology, and 4 DLBCL with MYC rearrangement (MYC-R), using targeted next-generation sequencing and the aggressive lymphoma gene expression germinal center B-cell-like (GCB), activated B-cell-like (ABC), and dark zone signatures (DZsig). Twenty-two tumors had MYC-R without BCL2 breaks, and two MYC-non-R cases had BCL6 translocations. MYC-R cases, including DLBCL, carried BL-related mutations and copy number alterations. Conversely, MYC-non-R lymphomas had alterations in the B-cell receptor signaling/NF-κB pathway (71%). DZsig was expressed in 12/13 of MYC-R tumors but only in 2/10 of MYC-non-R GCB tumors (P < 0.001). The 3-year event-free survival (EFS) of the whole cohort was 79.6%. TP53 and KMT2C mutations conferred inferior outcome (3-year EFS P < 0.05). Overall, MYC-R lymphomas in CAYA have a molecular profile similar to BL regardless of their high-grade or DLBCL morphology, whereas MYC-non-R has more heterogeneous genetic alterations closer to that of DLBCL.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
儿童和年轻人中的 MYC 重排成熟 B 细胞淋巴瘤在分子上属于伯基特淋巴瘤
儿童、青少年和年轻成人(CAYA)中的侵袭性 B 细胞非霍奇金淋巴瘤(NHL)包括伯基特淋巴瘤(BL)、弥漫大 B 细胞淋巴瘤(DLBCL)以及具有介于这些实体之间特征的高级别肿瘤亚群,这些肿瘤的遗传和分子特征尚未完全阐明。在这项研究中,我们利用靶向新一代测序技术和侵袭性淋巴瘤基因表达生殖中心B细胞样(GCB)、活化B细胞样(ABC)和暗区特征(DZsig),对CAYA中的37个侵袭性B-NHL(33个具有高级别形态)和4个具有MYC重排(MYC-R)的DLBCL进行了鉴定。22例肿瘤有MYC-R而无BCL2断裂,2例MYC-non-R病例有BCL6易位。MYC-R病例(包括DLBCL)携带BL相关突变和拷贝数改变。相反,MYC-non-R淋巴瘤的B细胞受体信号/NF-κB通路发生了改变(71%)。有12/13的MYC-R肿瘤表达DZsig,但只有2/10的MYC-non-R GCB肿瘤表达DZsig(P <0.001)。整个群体的3年无事件生存率(EFS)为79.6%。TP53和KMT2C突变会导致较差的预后(3年EFS P < 0.05)。总的来说,CAYA中的MYC-R淋巴瘤无论其形态是高级别还是DLBCL,其分子谱都与BL相似,而MYC-non-R则具有更接近DLBCL的异质性基因改变。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
16.70
自引率
2.30%
发文量
153
审稿时长
>12 weeks
期刊介绍: Blood Cancer Journal is dedicated to publishing high-quality articles related to hematologic malignancies and related disorders. The journal welcomes submissions of original research, reviews, guidelines, and letters that are deemed to have a significant impact in the field. While the journal covers a wide range of topics, it particularly focuses on areas such as: Preclinical studies of new compounds, especially those that provide mechanistic insights Clinical trials and observations Reviews related to new drugs and current management of hematologic malignancies Novel observations related to new mutations, molecular pathways, and tumor genomics Blood Cancer Journal offers a forum for expedited publication of novel observations regarding new mutations or altered pathways.
期刊最新文献
Venetoclax combined with three-day multi-frequency decitabine (DEC3-VEN) in elder or intensive chemotherapy ineligible patients with newly diagnosed acute myeloid leukemia. Frontline Ph-negative B-cell precursor acute lymphoblastic leukemia treatment and the emerging role of blinatumomab What have we learned about TP53-mutated acute myeloid leukemia? Impact of TP53 mutation on genetic and cellular hierarchy profile in complex karyotype AML/MDS with increased blasts A simplified, two-factor clinical prognostic scoring system for patients with newly diagnosed Hodgkins Lymphoma
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1